In a victory for the European Medicines Agency, a European court ruled the regulator can provide access to clinical trial data and other types of information over the objections of three drug makers that claimed greater transparency would come at the expense of their commercial secrets.
The cases have been closely watched as a test of transparency rules that the EMA implemented seven years ago, as well as a newer policy that permits the agency to release certain clinical trial data, while also agreeing to select redactions negotiated with companies.
May I observe that since this is a European matter, the ‘Merck’ in question might be more properly tagged “MS&D?” (Merck Sharp & Dhome)
That takes nothing away from the valuable detail in the article, which one expects will be updated as usual by additional company comments, as they arrive.
Comments are closed.